Arca Biopharma: Rises On Fda's 'fast: track' tag for COVID-19 treatment

Oruka Therapeutics

23/11/2020 13:55

** Drug developer's shares  ABIO.O  rise 10% to $4.28
premarket
    ** Co says the U.S. FDA has granted "fast-track" status to
AB201 as a potential treatment for COVID-19  urn:newsml:reuters.com:*:nGNX6G5BHH
    ** Co says it intends to start mid-stage clinical trial of
AB201 in 100 patients hospitalized with COVID-19 in December
2020, with top-line data expected in Q2 of 2021
    ** AB201's combination of anti-inflammatory and antiviral
effects may favorably impact clinical recovery of patients
hospitalized with COVID-19 - CEO Michael Bristow
    ** Up to last close, ABIO stock down ~31% this year

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))